Clinical Trials
2173
276 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1885
Terminated
196
9.0%
Recruiting
253
11.6%
Suspended
10
0.5%
Approved For Marketing
2
0.1%
Withdrawn
174
8.0%
Active, not recruiting
79
3.6%
Unknown
23
1.1%
Completed
1239
57.0%
Enrolling By Invitation
47
2.2%
Not yet recruiting
150
6.9%
No approval data available
- The Clear Labels Act, which would show where a drug was manufactured on its label, is headed to a full Senate vote after two key provisions were removed. - Senators struck the requirement to print the FDA's unique facility identifier, a DUNS number, and extended compliance from one year to five. - Drug safety experts and former FDA inspectors say the revised bill's address-only requirement will be hard to trace and enforce.
- TwoStep Therapeutics closed an oversubscribed $62.5 million Series A, bringing total capital raised to $71.2 million to fund oncology development. - The FDA cleared the IND for TS-104, a first-in-class multi-specific peptide-drug conjugate, allowing a first-in-human Phase 1 trial to begin. - TS-104 pairs a polyspecific integrin-binding peptide with the cytotoxic payload MMAE to target five tumor-associated integrins simultaneously. - The company says proceeds will also advance a radioligand therapy program and next-generation peptide conjugates built on the same PIP scaffold.
- Novonesis is partnering with Metropolitan Community College in Omaha to shape a new biotechnology technician training program and launch the Novonesis Biomanufacturing Pathways Scholarship. - Nebraska bioscience employment grew 6.3% from 2019 to 2023, outpacing the state's 2.9% overall private-sector growth, underscoring demand for skilled workers. - The initiative includes a 15-week Biotechnology Fundamentals Microcredential, a Biotechnology Career Certificate, job shadowing, facility tours, and recruiter screening for graduates. - The Nebraska effort is part of a broader national strategy spanning K-12 outreach, community college partnerships, and university research collaborations across 14 North American sites.
- A Penn State-led team developed STREAM, a platform that rapidly grows and analyzes bacteria to identify bloodstream infection pathogens in as little as seven hours, versus two to seven days for conventional culturing. - The approach integrates single-cell imaging, computer algorithms, and antibiotic susceptibility testing to simultaneously name the pathogen and recommend effective antibiotics before sepsis develops. - Testing on about 100 positive blood samples showed comprehensive diagnosis within hours, though a 4% "very major error" rate and challenges with pre-treated patients remain hurdles before clinical use. - The framework offers a scalable foundation that could expand to fungal infections and aims to curb worsening antibiotic resistance through faster, more targeted treatment.
- Stanford Medicine researchers are engineering immune cells to follow the metabolic "scent" cancer leaves behind, turning them into "bloodhounds" that better track and infiltrate solid tumors. - The approach aims to address the difference between a treatment that stays in the bloodstream and one that actually reaches the tumor, which can "mean everything" for patients. - The research remains early-stage and has so far been demonstrated in mice, with advocates calling for continued funding of precision medicine approaches. - The development is framed within the broader legacy of precision medicine, including the first targeted therapy that gave chronic myeloid leukemia survivor Mel Mann more than 30 years of life.
- The Richard King Mellon Foundation has committed up to $25 million to launch Rare Ventures, a first-of-its-kind venture philanthropy platform for accelerating rare disease therapies. - The initiative unites Carnegie Mellon University, the University of Pittsburgh, UPMC, Stanford Medicine, ElevateBio, and the EB Research Partnership to combine AI, clinical research, and therapeutic development. - More than 400 million people worldwide live with a rare disease, yet approximately 95% of the 10,000+ rare diseases lack an approved treatment. - Rare Ventures builds on EBRP's 14-year track record, which helped fund over 180 research projects and contributed to three FDA-approved therapies for epidermolysis bullosa.
- Anthropic announced an 85% reduction in Claude Fable 5's biology-related fallbacks, allowing patients, students, and healthcare clinicians direct access to the model's frontier reasoning on health questions. - The update recalibrates the safety classifier's constitution to carve out benign uses while maintaining blocks on dual-use domains including virology, toxicology, and molecular design. - Professional researchers in drug development and biology remain unable to use Fable 5, with no timeline given for the trusted-access pathway promised at the model's June 9 launch. - The announcement coincided with Stanford researchers publishing proof that genome language models can design functional viral genomes, intensifying the dual-use debate.
- Scientists at Stanford University and Arc Institute used AI genome language models Evo 1 and Evo 2 to design entirely new viruses capable of infecting E. coli bacteria. - The models, trained on trillions of nucleotides and roughly 15,000 viruses, generated 700,000 candidates; 16 proved viable, with some reproducing faster than the natural Phi X-174 virus. - The research, published in Science, could accelerate gene therapy and biotechnology breakthroughs but has drawn urgent warnings from biosecurity experts about potential misuse for biological weapons. - Biosecurity leaders Dr. Thomas Inglesby and Dr. Moritz Hanke called for strict laws prohibiting similar generative techniques on pathogens affecting humans, animals, or agricultural crops.
- Natural language processing models analyzing children's speech predicted psychiatric diagnoses six years later more accurately than human expert panels using standard clinical assessments. - Structural speech style—function words like conjunctions, prepositions, and pronouns—proved far more predictive of future mental illness than the semantic content of trauma descriptions. - Descriptions of physical violence and social exclusion correlated with elevated risk, while mentions of social support, activities, and mental healthcare signaled resilience. - Speech analysis offers a low-cost, scalable, non-invasive biomarker that could enable smartphone-based screening during the critical pre-diagnosis window of ages 9 to 13.
- The American Academy of Sleep Medicine advocates for permanent standard time, arguing it best aligns with human circadian biology and natural morning light cues. - Studies link social jet lag—the misalignment between social clocks and solar time—to increased risks of obesity, diabetes, cardiovascular disease, and shorter sleep duration. - A 2019 Journal of Health Economics study found that people living farther west within a time zone had worse health outcomes due to chronic circadian disruption. - The Sunshine Protection Act, which would make daylight saving time permanent, raises concerns about darker winter mornings and children commuting to school before sunrise.
